• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

>30 Percent With Migraine Experience Migraine-Related Stigma Often

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 19, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Jan. 18, 2024 -- More than 30 percent of individuals with migraine experience migraine-related stigma often or very often, according to a study published online Jan. 17 in Neurology.

Robert E. Shapiro, M.D., Ph.D., from the Larner College of Medicine at the University of Vermont in Burlington, and colleagues examined the association between migraine-related stigma with migraine outcomes in a study involving people identified with active migraine using a validated migraine diagnostic questionnaire. The frequency of experiencing migraine-related stigma was assessed using a 12-item questionnaire (Migraine-Related Stigma [MiRS]), which included two factors: feeling that others perceived that migraine was used for "Secondary Gain" and feeling that others were "Minimizing Burden."

The researchers found that 41.1 percent of the 59,001 respondents with active migraine reported experiencing at least four monthly headache days, and 31.7 percent experienced migraine-related stigma often/very often. There was an increase observed in the proportion experiencing migraine-related stigma often/very often from 25.5 to 47.5 percent among those with fewer than four and 15 or more monthly headache days, respectively. The risk for increased disability was significant for each MiRS group versus the MiRS-Never group; the MiRS-Both (Secondary Gain and Minimizing Burden often/very often) group had a more than twofold increased risk (rate ratio, 2.68). There was an association seen between increased migraine-related stigma and increased disease burden across all monthly headache day categories for disability, interictal burden, and migraine-specific quality of life.

"Clarifying the mechanisms that link stigma to health outcomes could set the stage for interventions that may reduce the burdens of migraine across the full spectrum of headache frequency," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Eli Lilly, which funded the study.

Abstract/Full Text

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted January 2024

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.